Castle Biosciences, Inc. (CSTL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Derek J. Maetzold | Founder, CEO, President & Director | 1.66M | 198.65k | 1962 |
| Mr. Frank Stokes | CFO & Treasurer | 926.74k | -- | 1971 |
| Ms. Kristen M. Oelschlager R.N. | Chief Operating Officer | 1.21M | -- | 1968 |
| Mr. Tobin W. Juvenal | Chief Commercial Officer | 883.19k | 263.2k | 1961 |
| Ms. Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs | -- | -- | -- |
| Mr. Kevin Doman | Vice President of Sales | -- | -- | -- |
| Dr. Jay Braxton Pharm.D. | VP of Marketing & Brand Manager of Uveal Melanoma (UM) | -- | -- | -- |
| Ms. Keli Greenberg | Vice President of Human Resources | -- | -- | -- |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical | -- | -- | -- |
Castle Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 761
Description
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Corporate Governance
Upcoming Events
May 5, 2025 at 8:00 PM UTC
Castle Biosciences, Inc. Earnings Date
Recent Events
April 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission